このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

RedHill Biopharma バランスシートの健全性

財務の健全性基準チェック /56

RedHill Biopharmaの総株主資本は$2.1M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$23.0Mと$21.0Mです。

主要情報

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	US$5.57m
エクイティ	US$2.07m
負債合計	US$20.98m
総資産	US$23.05m

財務の健全性に関する最新情報

Recent updates

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

Jul 28

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Oct 18

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Dec 02

財務状況分析

短期負債: RDHLの短期資産 ( $16.1M ) は短期負債 ( $19.2M ) をカバーしていません。

長期負債: RDHLの短期資産 ( $16.1M ) が長期負債 ( $1.7M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: RDHLは負債がありません。

負債の削減: RDHL 5 年前には負債がありませんでした。

債務返済能力: RDHLには負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: RDHLには負債がないため、利息支払いの負担は問題になりません。

RedHill Biopharma バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma Ordinary Shares Deleted from Other OTC

Recent updates

RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board

RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035

RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Full year 2023 earnings released: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $1.25 million.

New minor risk - Financial data availability

Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

Investor sentiment deteriorates as stock falls 15%

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investor sentiment deteriorates as stock falls 22%

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

Investor sentiment improves as stock rises 615%

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

RedHill Biopharma Ltd. announced that it has received $4.043808 million in funding

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®?

RedHill Biopharma Ltd. Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA)

New minor risk - Earnings quality

Second quarter 2023 earnings released

RedHill Biopharma Ltd. Announces its Partner, Gaelan Medical LLC Receives Marketing Approval from United Arab Emirates Ministry of Health for Talicia

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

New major risk - Share price stability

RedHill Biopharma Ltd., Annual General Meeting, Aug 08, 2023

First quarter 2023 earnings released: EPS: US$20.00 (vs US$15.64 loss in 1Q 2022)

New major risk - Revenue and earnings growth

RedHill Biopharma Ltd. Provides R&D Update

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Redhill Biopharma Ltd. Announces Board Changes

Full year 2022 earnings released: US$48.00 loss per share (vs US$84.03 loss in FY 2021)

Redhill Biopharma Ltd. Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 for Oncology Support

RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

Redhill Biopharma Ltd. Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB 107 in Non-Hospitalized COVID-19

RedHill Biopharma Ltd. has completed a Composite Units Offering in the amount of $7.989775 million.

RedHill Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of $8 million.

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.46 loss in 3Q 2021)

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Consensus forecasts updated

Redhill Biopharma Ltd. Announces Positive New Data with Opaganib for Nuclear Radiation Injury

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

RedHill Biopharma Ltd. Provides Earnings Guidance for the Third Quarter Ended September 30, 2022

RedHill Biopharma Ltd. Presents New Talicia® Data Analyses At Obesity Week 2022

Insufficient new directors

Redhill Biopharma Ltd. Announces Presentation of New Data Analyses for Talicia

RedHill Biopharma Ltd. Announces Grant of New COVID-19 Treatment Patent for its Oral Broad-Acting Antiviral, Opaganib

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Redhill Biopharma Ltd. Announces Study Results Showing in Vitro Efficacy Against the Currently Dominant Omicron Covid-19 Sub-Variant BA.5

Insufficient new directors

RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease

Consensus forecasts updated

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.53 loss in 1Q 2021)

RedHill Biopharma Ltd. to Report Q1, 2022 Results on Jun 23, 2022

Price target decreased to US$13.60

RedHill Presents New Talicia Data Analyses at DDW 2022

RedHill: Given Up For Dead

Forecast breakeven date moved forward to 2023

RedHill Biopharma Ltd. Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

RedHill Biopharma Ltd., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

Price target decreased to US$14.14

RedHill Biopharma: Looking At An Unexciting Dead-End

財務の健全性基準チェック /56